RxDoctor Payments Data

Daljinder Takhar, DO

Family Medicine · Ontario, CANPI 1467562249

Payments from drug & device makers

$9,180in general payments, 2019–2025

Across 514 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • AbbVie$688
  • Teva Pharmaceuticals USA, Inc.$678
  • Novo Nordisk$665
  • Johnson & Johnson$606
  • Novartis$596
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$9,06299%
  • Education$1181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,180 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$180,110
Medicare patients
245
Services billed
4,996

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban288$102,725
Austedo XrDeutetrabenazine12$77,701
JardianceEmpagliflozin88$67,115
JanuviaSitagliptin Phosphate126$66,351
MounjaroTirzepatide47$54,554
OzempicSemaglutide52$46,845
XareltoRivaroxaban67$34,833
ProliaDenosumab15$24,484
GemtesaVibegron51$19,521
EntrestoSacubitril/Valsartan39$18,472
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$14,725
Pantoprazole Sodium176$14,647
FarxigaDapagliflozin Propanediol11$11,892
ProcritEpoetin Alfa15$11,865
BrilintaTicagrelor31$11,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$492$102,725288 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$678$77,70112 claims
Boehringer IngelheimJardiance$70$67,11588 claims
MerckJanuvia$33$66,351126 claims
Lilly USA, LLCMounjaro$484$54,55447 claims
Novo NordiskOzempic$665$46,84552 claims
Johnson & JohnsonXarelto, Procrit$606$46,69882 claims
AmgenProlia, Epogen$1,713$29,30938 claims
AstraZenecaFarxiga, Brilinta, Symbicort$314$27,46259 claims
Sumitomo Pharma America, Inc.Gemtesa$179$19,52151 claims
NovartisEntresto$596$18,47239 claims
GSKTrelegy Ellipta, Arnuity Ellipta$122$17,02237 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Ontario

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →